Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4Expanded_access 2

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Carcinoma, Hepatocellular 2Tuberous Sclerosis 1Recurrence 1Prostate Cancer Patients 1Neoplasms 1Lymphangioleiomyomatosis 1Glioma 1Glioblastoma 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

Docetaxel 277Prednisone 237enzalutamide 177Leuprolide 172Radiotherapy 164Abiraterone Acetate 154Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 79abiraterone 77gallium 68 PSMA-11 74Specimen Handling 67darolutamide 58Gonadotropin-Releasing Hormone 58Radiation 56Triptorelin Pamoate 53cabazitaxel 50Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × carbon-11 acetate × Clear all
NCT01304485 2019-03-07

PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Phoenix Molecular Imaging

Phase 2 Completed
2,000 enrolled
Genitourinary

Prostatic Neoplasms

NCT01144897 2018-10-02

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

University of Iowa

Phase 1 Completed
5 enrolled
Genitourinary

Prostatic Neoplasms

NCT00924313 2017-07-11

Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
40 enrolled 17 charts
Genitourinary

Prostatic Neoplasms

NCT02169063 2016-08-31

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

University of Washington

Phase NA Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡